Compare AERT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | NOTV |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 23.0M |
| IPO Year | N/A | 1997 |
| Metric | AERT | NOTV |
|---|---|---|
| Price | $0.54 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 130.4K | ★ 418.8K |
| Earning Date | 02-13-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $69,346,000.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.49 |
| Revenue Next Year | N/A | $4.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $0.46 | $0.60 |
| 52 Week High | $2.67 | $5.67 |
| Indicator | AERT | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 29.66 |
| Support Level | $0.54 | $0.61 |
| Resistance Level | $0.59 | $0.69 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 11.75 | 2.55 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.